Biomarkers of pathophysiology in hypertrophic cardiomyopathy: implications for clinical management and prognosis.
The study of biomarkers and their signalling pathways has allowed the development of new therapeutic strategies in a range of disorders. The aim of the present systematic review is to provide an overview of different biomarkers in patients with hypertrophic cardiomyopathy that could give some insight into the pathophysiologic mechanism(s) underlying the typical clinical and histological manifestations of the disease. Several pathophysiological models are presented and discussed, including studies that have investigated these biomarkers for diagnostic and prognostic reasons, in relation to disease progression and/or mortality.
Cambronero
Francisco
F
Department of Cardiology, Hospital Universitario Virgen de la Arrixaca, Murcia, Spain.
Marín
Francisco
F
Roldán
Vanessa
V
Hernández-Romero
Diana
D
Valdés
Mariano
M
Lip
Gregory Y H
GY
D015415:Biomarkers / Q000378:metabolism*; D002312:Cardiomyopathy, Hypertrophic / Q000175:diagnosis / Q000209:etiology* / Q000378:metabolism / Q000401:mortality; D004730:Endothelium, Vascular / Q000503:physiopathology; D006801:Humans; D008954:Models, Biological; D011379:Prognosis
D015415:Biomarkers